Article

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokines

2025-04-10

Abstract excerpt

<title>Abstract</title> <p>Non-small cell lung cancer (NSCLC) is frequently associated with mutations in receptor tyrosine kinases (RTKs), such as EGFR and ALK. While RTK inhibitors (RTKIs) have proven effective in treating patients with specific RTK mutations, the emergence of resistance to these therapies remains a significant clinical obstacle. As such, there is still an unmet need for the identification of ne...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 29cbbfa5-6f09-5cb8-8057-f9ae4c17ccbc
DOI: 10.21203/rs.3.rs-5661974/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

MED12 mutation induces RTK inhibitor resistance in NSCLC via MEK/ERK pathway activation by inflammatory cytokinesDOI 10.21203/rs.3.rs-5661974/v1Read

MicroRNAs as the critical regulators of tyrosine kinase inhibitors resistance in lung tumor cells.Semantic proximity Read

Increased PD-L1 expression in erlotinib-resistant NSCLC cells with MET gene amplification is reversed upon MET-TKI treatmentSemantic proximity Read

Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells.Semantic proximity Read

MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor SignalingSemantic proximity Read

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC.Semantic proximity Read

TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancerSemantic proximity Read

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read

MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.Semantic proximity Read

STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell linesSemantic proximity Read

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancerSemantic proximity Read

Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.Semantic proximity Read

EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.Semantic proximity Read